Hsbc Holdings PLC Purchases 11,762 Shares of Quanterix Corporation $QTRX

Hsbc Holdings PLC grew its stake in Quanterix Corporation (NASDAQ:QTRX) by 60.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 31,133 shares of the company’s stock after acquiring an additional 11,762 shares during the period. Hsbc Holdings PLC owned 0.08% of Quanterix worth $200,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Tower Research Capital LLC TRC raised its stake in shares of Quanterix by 219.1% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,702 shares of the company’s stock worth $61,000 after acquiring an additional 3,915 shares during the last quarter. Quantbot Technologies LP raised its stake in shares of Quanterix by 245.9% in the first quarter. Quantbot Technologies LP now owns 11,272 shares of the company’s stock worth $73,000 after acquiring an additional 8,013 shares during the last quarter. Aaron Wealth Advisors LLC bought a new position in shares of Quanterix in the first quarter worth about $79,000. Allspring Global Investments Holdings LLC bought a new position in shares of Quanterix in the first quarter worth about $98,000. Finally, ProShare Advisors LLC bought a new position in shares of Quanterix in the fourth quarter worth about $108,000. 86.48% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Canaccord Genuity Group reaffirmed a “hold” rating and issued a $5.00 target price (down from $12.00) on shares of Quanterix in a research note on Monday, August 11th. Wall Street Zen downgraded shares of Quanterix from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. One analyst has rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Quanterix currently has a consensus rating of “Hold” and an average price target of $11.75.

Quanterix Price Performance

QTRX opened at $4.55 on Friday. The company has a market cap of $211.44 million, a price-to-earnings ratio of -2.50 and a beta of 1.03. The firm has a 50 day simple moving average of $5.44 and a 200 day simple moving average of $5.86. Quanterix Corporation has a fifty-two week low of $4.05 and a fifty-two week high of $15.85.

Quanterix (NASDAQ:QTRX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.06). The business had revenue of $24.48 million for the quarter, compared to the consensus estimate of $29.73 million. Quanterix had a negative return on equity of 18.41% and a negative net margin of 56.04%. Quanterix has set its FY 2025 guidance at EPS. As a group, analysts expect that Quanterix Corporation will post -0.98 EPS for the current year.

Insider Transactions at Quanterix

In other news, Director David R. Walt acquired 123,990 shares of the firm’s stock in a transaction that occurred on Friday, June 13th. The stock was purchased at an average price of $6.14 per share, for a total transaction of $761,298.60. Following the completion of the acquisition, the director owned 1,866,933 shares in the company, valued at $11,462,968.62. This trade represents a 7.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 238,131 shares of company stock worth $1,402,860 in the last ninety days. 6.80% of the stock is currently owned by insiders.

Quanterix Company Profile

Quanterix Corporation, a life sciences company, engages in development and marketing of digital immunoassay platforms that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company offers HD-X instrument, a protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection in an expanded range of applications.